BNP Paribas Asset Management
ADMA icon

BNP Paribas Asset Management’s ADMA Biologics ADMA Stock Holding History

BNP Paribas Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.3K Buy
3,923
+858
+28% +$13.5K ﹤0.01% 1860
2025
Q4 		$56K Buy
3,065
+836
+38% +$14.1K ﹤0.01% 1627
2025
Q3 		$33K Hold
2,229
– – ﹤0.01% 1188
2025
Q2 		$41K Buy
+2,229
New +$45.5K ﹤0.01% 1209

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

BNP Paribas Asset Management's ADMA Position: Q1 2026 in Review

BNP Paribas Asset Management increased its ADMA Biologics (ADMA) stake by 28% in Q1 2026, buying an estimated $13.5K and bringing the position to 3,923 shares worth $35.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1860.

BNP Paribas Asset Management first reported a position in ADMA in Q2 2025 and has held it in 4 quarters since. The position peaked at $56K in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • BNP Paribas Asset Management held 3,923 shares of ADMA Biologics worth $35.3K as of Q1 2026.
  • BNP Paribas Asset Management bought 858 ADMA Biologics shares in Q1 2026, an estimated $13.5K.
  • ADMA Biologics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #1860 holding.
  • BNP Paribas Asset Management first reported a position in ADMA Biologics in Q2 2025 and has held it in 4 quarters since.
  • BNP Paribas Asset Management's ADMA Biologics position peaked at $56K in Q4 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.